Patents by Inventor Woonza M. Rhee

Woonza M. Rhee has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210228764
    Abstract: The present invention provides a hemostatic composite sponge comprising oxidized cellulose and an essentially gelatin-free bioadhesive material stably associated with said sponge and present in an organized pattern on said sponge.
    Type: Application
    Filed: April 15, 2021
    Publication date: July 29, 2021
    Inventors: Hans Christian Hedrich, Joris Hoefinghoff, Woonza M. Rhee, Atsushi Edward Osawa
  • Patent number: 11071804
    Abstract: The present invention provides a hemostatic composite sponge comprising oxidized cellulose and an essentially gelatin-free bioadhesive material stably associated with said sponge and present in an organized pattern on said sponge.
    Type: Grant
    Filed: December 15, 2017
    Date of Patent: July 27, 2021
    Assignees: Baxter International Inc., Baxter Healthcare SA
    Inventors: Hans Christian Hedrich, Joris Hoefinghoff, Woonza M. Rhee, Atsushi Edward Osawa
  • Publication number: 20180104377
    Abstract: The present invention provides a hemostatic composite sponge comprising oxidized cellulose and an essentially gelatin-free bioadhesive material stably associated with said sponge and present in an organized pattern on said sponge.
    Type: Application
    Filed: December 15, 2017
    Publication date: April 19, 2018
    Inventors: Hans Christian Hedrich, Joris Hoefinghoff, Woonza M. Rhee, Atsushi Edward Osawa
  • Patent number: 9872934
    Abstract: The present invention provides a hemostatic composite sponge comprising a porous matrix of a biomaterial and a bioadhesive material stably associated with said sponge and present in an organized pattern on said sponge.
    Type: Grant
    Filed: December 1, 2016
    Date of Patent: January 23, 2018
    Assignees: Baxter International Inc., Baxter Healthcare SA
    Inventors: Hans Christian Hedrich, Joris Hoefinghoff, Woonza M. Rhee, Atsushi Edward Osawa
  • Publication number: 20170080119
    Abstract: The present invention provides a hemostatic composite sponge comprising a porous matrix of a biomaterial and a bioadhesive material stably associated with said sponge and present in an organized pattern on said sponge.
    Type: Application
    Filed: December 1, 2016
    Publication date: March 23, 2017
    Inventors: Hans Christian Hedrich, Joris Hoefinghoff, Woonza M. Rhee, Atsushi Edward Osawa
  • Patent number: 9517287
    Abstract: The present invention provides a hemostatic composite sponge comprising a porous matrix of a biomaterial and a material enhancing the adherence of said sponge to the applied tissue stably associated with at least one surface of said sponge, a method of producing these sponges and their use in hemostasis.
    Type: Grant
    Filed: June 30, 2014
    Date of Patent: December 13, 2016
    Assignees: Baxter International, Inc., Baxter Healthcare, S.A.
    Inventors: Hans Christian Hedrich, Joris Hoefinghoff, Woonza M. Rhee, Atsushi Edward Osawa
  • Patent number: 9114172
    Abstract: Compositions, methods, and kits are provided for sealing applications. Compositions are prepared by combining a first cross-linkable component with a second cross-linkable component to form a porous matrix having interstices, and combining the porous matrix with a hydrogel-forming component to fill at least some of the interstices. The compositions exhibit minimal swelling properties.
    Type: Grant
    Filed: February 28, 2013
    Date of Patent: August 25, 2015
    Assignees: Baxter International Inc., Baxter Healthcare S.A.
    Inventors: Woonza M. Rhee, Cary J. Reich, A. Edward Osawa, Felix Vega
  • Patent number: 8962025
    Abstract: Compositions, methods, and kits are provided for sealing applications. Compositions are prepared by combining a first cross-linkable component with a second cross-linkable component to form a porous matrix having interstices, and combining the porous matrix with a hydrogel-forming component to fill at least some of the interstices. The compositions exhibit minimal swelling properties.
    Type: Grant
    Filed: August 1, 2007
    Date of Patent: February 24, 2015
    Assignees: Baxter International Inc., Baxter Healthcare S.A.
    Inventors: Woonza M. Rhee, Cary J. Reich, A. Edward Osawa, Felix Vega
  • Publication number: 20140378928
    Abstract: The present invention provides a hemostatic composite sponge comprising a porous matrix of a biomaterial and a material enhancing the adherence of said sponge to the applied tissue stably associated with at least one surface of said sponge, a method of producing these sponges and their use in hemostasis.
    Type: Application
    Filed: June 30, 2014
    Publication date: December 25, 2014
    Inventors: Hans Christian Hedrich, Joris Hoefinghoff, Woonza M. Rhee, Atsushi Edward Osawa
  • Patent number: 8771258
    Abstract: The present invention provides a hemostatic composite sponge comprising a porous matrix of a biomaterial and a material enhancing the adherence of said sponge to the applied tissue stably associated with at least one surface of said sponge, a method of producing these sponges and their use in hemostasis.
    Type: Grant
    Filed: December 16, 2010
    Date of Patent: July 8, 2014
    Assignees: Baxter International Inc., Baxter Healthcare S.A.
    Inventors: Hans Christian Hedrich, Joris Hoefinghoff, Woonza M. Rhee, Atsushi Edward Osawa
  • Publication number: 20120207813
    Abstract: Compositions, methods, and kits are provided for sealing applications. Compositions are prepared by combining a first cross-linkable component with a second cross-linkable component to form a porous matrix having interstices, and combining the porous matrix with a hydrogel-forming component to fill at least some of the interstices. The compositions exhibit minimal swelling properties.
    Type: Application
    Filed: April 26, 2012
    Publication date: August 16, 2012
    Applicants: Baxter Healthcare S.A., Baxter International Inc.
    Inventors: Woonza M. RHEE, Cary J. REICH, A. Edward OSAWA, Felix VEGA
  • Patent number: 8197802
    Abstract: Provided are crosslinked polymer compositions that include a first synthetic polymer containing multiple nucleophilic groups covalently bound to a second synthetic polymer containing multiple electrophilic groups. The first synthetic polymer is preferably a synthetic polypeptide or a polyethylene glycol that has been modified to contain multiple nucleophilic groups, such as primary amino (—NH2) or thiol (—SH) groups. The second synthetic polymer may be a hydrophilic or hydrophobic synthetic polymer, which contains or has been derivatized to contain, two or more electrophilic groups, such as succinimidyl groups. The compositions may further include other components, such as naturally occurring polysaccharides or proteins (such as glycosaminoglycans or collagen) and/or biologically active agents.
    Type: Grant
    Filed: December 28, 2010
    Date of Patent: June 12, 2012
    Assignee: AngioDevice International GmbH
    Inventors: Woonza M. Rhee, Frank A. DeLustro, Richard A. Berg
  • Publication number: 20110202026
    Abstract: The present invention provides a hemostatic composite sponge comprising a porous matrix of a biomaterial and a material enhancing the adherence of said sponge to the applied tissue stably associated with at least one surface of said sponge, a method of producing these sponges and their use in hemostasis.
    Type: Application
    Filed: December 16, 2010
    Publication date: August 18, 2011
    Applicants: Baxter International Inc., Baxter Healthcare S.A.
    Inventors: Hans Christian Hedrich, Joris Hoefinghoff, Woonza M. Rhee, Atsushi Edward Osawa
  • Publication number: 20110195040
    Abstract: Provided are crosslinked polymer compositions that include a first synthetic polymer containing multiple nucleophilic groups covalently bound to a second synthetic polymer containing multiple electrophilic groups. The first synthetic polymer is preferably a synthetic polypeptide or a polyethylene glycol that has been modified to contain multiple nucleophilic groups, such as primary amino (—NH2) or thiol (—SH) groups. The second synthetic polymer may be a hydrophilic or hydrophobic synthetic polymer, which contains or has been derivatized to contain, two or more electrophilic groups, such as succinimidyl groups. The compositions may further include other components, such as naturally occurring polysaccharides or proteins (such as glycosaminoglycans or collagen) and/or biologically active agents.
    Type: Application
    Filed: December 28, 2010
    Publication date: August 11, 2011
    Applicant: ANGIODEVICE INTERNATIONAL GMBH
    Inventors: Woonza M. Rhee, Frank A. DeLustro, Richard A. Berg
  • Patent number: 7883694
    Abstract: Provided are crosslinked polymer compositions that include a first synthetic polymer containing multiple nucleophilic groups covalently bound to a second synthetic polymer containing multiple electrophilic groups. The first synthetic polymer is preferably a synthetic polypeptide or a polyethylene glycol that has been modified to contain multiple nucleophilic groups, such as primary amino (—NH2) or thiol (—SH) groups. The second synthetic polymer may be a hydrophilic or hydrophobic synthetic polymer, which contains or has been derivatized to contain, two or more electrophilic groups, such as succinimidyl groups. The compositions may further include other components, such as naturally occurring polysaccharides or proteins (such as glycosaminoglycans or collagen) and/or biologically active agents.
    Type: Grant
    Filed: January 27, 2004
    Date of Patent: February 8, 2011
    Assignee: AngioDevice International GmbH
    Inventors: Woonza M. Rhee, Frank A. DeLustro, Richard A. Berg
  • Publication number: 20090238857
    Abstract: The present invention discloses novel crosslinked biomaterial compositions which are prepared using hydrophobic polymers as a crosslinking agent. Preferred hydrophobic polymers are those that contain two or more reactive succinimidyl groups, including disuccinimidyl suberate, bix(sulfosuccinimidyl) suberate, and dithiobis(succinimidylpropionate). Crosslinked biomaterial compositions prepared using mixtures of hydrophobic and hydrophilic crosslinking agents are also disclosed. The compositions of the present invention can be used to prepare formed implants for use in a variety of medical applications.
    Type: Application
    Filed: February 18, 2009
    Publication date: September 24, 2009
    Applicant: Angiotech Pharmaceuticals (US), Inc.
    Inventor: Woonza M. Rhee
  • Publication number: 20080187591
    Abstract: Compositions, methods, and kits are provided for sealing applications. Compositions are prepared by combining a first cross-linkable component with a second cross-linkable component to form a porous matrix having interstices, and combining the porous matrix with a hydrogel-forming component to fill at least some of the interstices. The compositions exhibit minimal swelling properties.
    Type: Application
    Filed: August 1, 2007
    Publication date: August 7, 2008
    Applicants: Baxter International, Inc., Baxter Healthcare S.A.
    Inventors: Woonza M. Rhee, Cary J. Reich, A. Edward Osawa, Felix Vega
  • Patent number: 7176256
    Abstract: Crosslinked polymer compositions comprise a first synthetic polymer containing multiple nucleophilic groups covalently bound to a second synthetic polymer containing multiple electrophilic groups. The first synthetic polymer is preferably a synthetic polypeptide or a polyethylene glycol that has been modified to contain multiple nucleophilic groups, such as primary amino (—NH2)or thiol (—SH) groups. The second synthetic polymer may be a hydrophilic or hydrophobic synthetic polymer which contains, or has been derivatized to contain, two or more electrophilic groups, such as succinimidyl groups. The compositions may further comprise other components, such as naturally occurring polysaccharides or proteins (such as glycosaminoglycans or collagen) and/or biologically active agents.
    Type: Grant
    Filed: June 21, 2004
    Date of Patent: February 13, 2007
    Assignee: Angiotech Pharmaceuticals (US), Inc.
    Inventors: Woonza M. Rhee, Frank A. DeLustro, Richard A. Berg
  • Patent number: 7151135
    Abstract: Provided are crosslinked polymer compositions that include a first synthetic polymer containing multiple nucleophilic groups covalently bound to a second synthetic polymer containing multiple electrophilic groups. The first synthetic polymer is preferably a synthetic polypeptide or a polyethylene glycol that has been modified to contain multiple nucleophilic groups, such as primary amino (—NH2) or thiol (—SH) groups. The second synthetic polymer may be a hydrophilic or hydrophobic synthetic polymer, which contains or has been derivatized to contain, two or more electrophilic groups, such as succinimidyl groups. The compositions may further include other components, such as naturally occurring polysaccharides or proteins (such as glycosaminoglycans or collagen) and/or biologically active agents.
    Type: Grant
    Filed: March 10, 2005
    Date of Patent: December 19, 2006
    Assignee: Angiotech Pharmaceuticals (US), Inc.
    Inventors: Woonza M. Rhee, Frank A. DeLustro, Richard A. Berg
  • Patent number: 7129209
    Abstract: The present invention discloses novel crosslinked biomaterial compositions which are prepared using hydrophobic polymers as a crosslinking agent. Preferred hydrophobic polymers are those that contain two or more reactive succinimidyl groups, including disuccinimidyl suberate, bis(sulfosuccinimidyl)suberate, and dithiobis(succinimidyl)propionate. Crosslinked biomaterial compositions prepared using mixtures of hydrophobic and hydrophilic crosslinking agents are also disclosed. The compositions of the present invention can be used to prepare formed implants for use in a variety of medical applications.
    Type: Grant
    Filed: May 28, 2003
    Date of Patent: October 31, 2006
    Assignee: Angiotech Pharmaceuticlas (US), Inc.
    Inventor: Woonza M. Rhee